Quarterly Activities Report and Appendix 4C
Filed with ASX · · 13 pages · English
• World-first clinical trial milestone achieved with first patient enrolment and full dosing completed in clinical trial using TRP-8803 (IV-infused psilocin) to treat Binge Eating Disorder (BED) • First patient underwent two infusions successfully and safely, demonstrating controlled, repeatable psychedelic exposure and favourable tolerability of TRP-8803 • Ongoing trial momentum building with thr
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- First TRP-8803 BED patient shows broad clinical improvement
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
- $847,186 R&D Tax Incentive received
- First BED patient completes second TRP-8803 infusion
- First patient successfully dosed in TRP 8803 BED trial
Later from Entropy Neurodynamics
- Australian Patent Secures TRP 8803 Platform to 2042
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- FY25 R&D Tax Incentive received
- TRP-8803 delivers repeatable, high-intensity effect
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics